Indeed, recurrent genetic abnormalities (FLT3-ITD, NPM1, and CEBPA mutations) had no significant impact on OS as assessed via Cox multivariate analyses adjusted by treatment, unlike what was seen in younger AML patients. Here, NPM1 is linked to acute myeloid leukemia.